Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Jun;40(6):1426–1431. doi: 10.1128/aac.40.6.1426

Identification, cloning, and expression of the Escherichia coli pyrazinamidase and nicotinamidase gene, pncA.

R Frothingham 1, W A Meeker-O'Connell 1, E A Talbot 1, J W George 1, K N Kreuzer 1
PMCID: PMC163344  PMID: 8726014

Abstract

Pyrazinamide (PZA) is one of the three most important drugs for treatment of Mycobacterium tuberculosis infections. The antibacterial activity of PZA requires a bacterial enzyme, pyrazinamidase (PZAase), which hydrolyzes PZA to form pyrazinoic acid and ammonia. Most PZA-resistant clinical M. tuberculosis isolates lack PZAase activity. With the goal of eventually identifying and characterizing the M.tuberculosis PZAase gene, we began with the more tractable organism, Escherichia coli, which also has PZAase activity. We screened a transposon-generated E. coli insertion mutant library, using a qualitative PZAase assay. Two PZAase-negative mutants out of 4,000 colonies screened were identified. In each mutant, the transposon interrupted the same 639-bp open reading frame (ORF), ORF1. The expression of ORF1 on a multicopy plasmid complemented a PZAase-negative mutant, leading to PZAase activity levels approximately 10-fold greater than those of the wild type. PZA has a structure similar to that of nicotinamide, a pyridine nucleotide cycle intermediate, so we tested our strains for nicotinamidase activity (EC 3.5.1.19) (genetic locus pncA). The construct with multiple plasmid copies of ORF1 had an approximately 10-fold increase in levels of nicotinamidase activity. This overexpressing strain could utilize nicotinamide as a sole nitrogen source, through wild-type E. coli cannot. We conclude that a single E. coli enzyme accounts for both PZAase and nicotinamidase activities and that ORF1 is the E.coli PZAase and nicotinamidase gene, pncA.

Full Text

The Full Text of this article is available as a PDF (298.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Altamirano M., Marostenmaki J., Wong A., FitzGerald M., Black W. A., Smith J. A. Mutations in the catalase-peroxidase gene from isoniazid-resistant Mycobacterium tuberculosis isolates. J Infect Dis. 1994 May;169(5):1162–1165. doi: 10.1093/infdis/169.5.1162. [DOI] [PubMed] [Google Scholar]
  2. Altschul S. F., Gish W., Miller W., Myers E. W., Lipman D. J. Basic local alignment search tool. J Mol Biol. 1990 Oct 5;215(3):403–410. doi: 10.1016/S0022-2836(05)80360-2. [DOI] [PubMed] [Google Scholar]
  3. Bachmann B. J. Linkage map of Escherichia coli K-12, edition 8. Microbiol Rev. 1990 Jun;54(2):130–197. doi: 10.1128/mr.54.2.130-197.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bachmann B. J., Low K. B., Taylor A. L. Recalibrated linkage map of Escherichia coli K-12. Bacteriol Rev. 1976 Mar;40(1):116–167. doi: 10.1128/br.40.1.116-167.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bartolomé B., Jubete Y., Martínez E., de la Cruz F. Construction and properties of a family of pACYC184-derived cloning vectors compatible with pBR322 and its derivatives. Gene. 1991 Jun 15;102(1):75–78. doi: 10.1016/0378-1119(91)90541-i. [DOI] [PubMed] [Google Scholar]
  6. Cambau E., Sougakoff W., Besson M., Truffot-Pernot C., Grosset J., Jarlier V. Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin. J Infect Dis. 1994 Aug;170(2):479–483. doi: 10.1093/infdis/170.2.479. [DOI] [PubMed] [Google Scholar]
  7. Cambau E., Sougakoff W., Jarlier V. Amplification and nucleotide sequence of the quinolone resistance-determining region in the gyrA gene of mycobacteria. FEMS Microbiol Lett. 1994 Feb 1;116(1):49–54. doi: 10.1111/j.1574-6968.1994.tb06674.x. [DOI] [PubMed] [Google Scholar]
  8. Dickinson E. S., Sundaram T. K. Chromosomal location of a gene defining nicotinamide deamidase in Escherichia coli. J Bacteriol. 1970 Mar;101(3):1090–1091. doi: 10.1128/jb.101.3.1090-1091.1970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Edlin B. R., Tokars J. I., Grieco M. H., Crawford J. T., Williams J., Sordillo E. M., Ong K. R., Kilburn J. O., Dooley S. W., Castro K. G. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med. 1992 Jun 4;326(23):1514–1521. doi: 10.1056/NEJM199206043262302. [DOI] [PubMed] [Google Scholar]
  10. Frothingham R., Hills H. G., Wilson K. H. Extensive DNA sequence conservation throughout the Mycobacterium tuberculosis complex. J Clin Microbiol. 1994 Jul;32(7):1639–1643. doi: 10.1128/jcm.32.7.1639-1643.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Frothingham R., Wilson K. H. Sequence-based differentiation of strains in the Mycobacterium avium complex. J Bacteriol. 1993 May;175(10):2818–2825. doi: 10.1128/jb.175.10.2818-2825.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Gottesman M. M., Hicks M. L., Gellert M. Genetics and function of DNA ligase in Escherichia coli. J Mol Biol. 1973 Jul 15;77(4):531–547. doi: 10.1016/0022-2836(73)90221-0. [DOI] [PubMed] [Google Scholar]
  13. Hanahan D. Studies on transformation of Escherichia coli with plasmids. J Mol Biol. 1983 Jun 5;166(4):557–580. doi: 10.1016/s0022-2836(83)80284-8. [DOI] [PubMed] [Google Scholar]
  14. Heifets L. B., Iseman M. D., Crowle A. J., Lindholm-Levy P. J. Pyrazinamide is not active in vitro against Mycobacterium avium complex. Am Rev Respir Dis. 1986 Dec;134(6):1287–1288. doi: 10.1164/arrd.1986.134.6.1287. [DOI] [PubMed] [Google Scholar]
  15. Huebner R. E., Good R. C., Tokars J. I. Current practices in mycobacteriology: results of a survey of state public health laboratories. J Clin Microbiol. 1993 Apr;31(4):771–775. doi: 10.1128/jcm.31.4.771-775.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Iseman M. D. Treatment of multidrug-resistant tuberculosis. N Engl J Med. 1993 Sep 9;329(11):784–791. doi: 10.1056/NEJM199309093291108. [DOI] [PubMed] [Google Scholar]
  17. Jerlström P. G., Bezjak D. A., Jennings M. P., Beacham I. R. Structure and expression in Escherichia coli K-12 of the L-asparaginase I-encoding ansA gene and its flanking regions. Gene. 1989 May 15;78(1):37–46. doi: 10.1016/0378-1119(89)90312-0. [DOI] [PubMed] [Google Scholar]
  18. Kleckner N., Bender J., Gottesman S. Uses of transposons with emphasis on Tn10. Methods Enzymol. 1991;204:139–180. doi: 10.1016/0076-6879(91)04009-d. [DOI] [PubMed] [Google Scholar]
  19. Konno K., Feldmann F. M., McDermott W. Pyrazinamide susceptibility and amidase activity of tubercle bacilli. Am Rev Respir Dis. 1967 Mar;95(3):461–469. doi: 10.1164/arrd.1967.95.3.461. [DOI] [PubMed] [Google Scholar]
  20. Lotte A., Wasz-Hockert O., Poisson N., Engbaek H., Landmann H., Quast U., Andrasofszky B., Lugosi L., Vadasz I., Mihailescu P. Second IUATLD study on complications induced by intradermal BCG-vaccination. Bull Int Union Tuberc Lung Dis. 1988 Jun;63(2):47–59. [PubMed] [Google Scholar]
  21. Lotte A., Wasz-Höckert O., Poisson N., Dumitrescu N., Verron M., Couvet E. BCG complications. Estimates of the risks among vaccinated subjects and statistical analysis of their main characteristics. Adv Tuberc Res. 1984;21:107–193. [PubMed] [Google Scholar]
  22. Mackay A., Macleod T., Alcorn M. J., Laidlaw M., Macleod I. M., Millar J. S., Stack B. H., White R. G. Fatal disseminated BCG infection in an 18-year-old boy. Lancet. 1980 Dec 20;2(8208-8209):1332–1334. doi: 10.1016/s0140-6736(80)92398-3. [DOI] [PubMed] [Google Scholar]
  23. Miller M. A., Thibert L., Desjardins F., Siddiqi S. H., Dascal A. Testing of susceptibility of Mycobacterium tuberculosis to pyrazinamide: comparison of Bactec method with pyrazinamidase assay. J Clin Microbiol. 1995 Sep;33(9):2468–2470. doi: 10.1128/jcm.33.9.2468-2470.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Pardee A. B., Benz E. J., Jr, St Peter D. A., Krieger J. N., Meuth M., Trieshmann H. W., Jr Hyperproduction and purification of nicotinamide deamidase, a microconstitutive enzyme of Escherichia coli. J Biol Chem. 1971 Nov 25;246(22):6792–6796. [PubMed] [Google Scholar]
  25. Romão M. J., Turk D., Gomis-Rüth F. X., Huber R., Schumacher G., Möllering H., Rüssmann L. Crystal structure analysis, refinement and enzymatic reaction mechanism of N-carbamoylsarcosine amidohydrolase from Arthrobacter sp. at 2.0 A resolution. J Mol Biol. 1992 Aug 20;226(4):1111–1130. doi: 10.1016/0022-2836(92)91056-u. [DOI] [PubMed] [Google Scholar]
  26. Sićević S. Generalized BCG tuberculosis with fatal course in two sisters. Acta Paediatr Scand. 1972 Mar;61(2):178–184. doi: 10.1111/j.1651-2227.1972.tb15922.x. [DOI] [PubMed] [Google Scholar]
  27. Stoeckle M. Y., Guan L., Riegler N., Weitzman I., Kreiswirth B., Kornblum J., Laraque F., Riley L. W. Catalase-peroxidase gene sequences in isoniazid-sensitive and -resistant strains of Mycobacterium tuberculosis from New York City. J Infect Dis. 1993 Oct;168(4):1063–1065. doi: 10.1093/infdis/168.4.1063. [DOI] [PubMed] [Google Scholar]
  28. Stover C. K., de la Cruz V. F., Fuerst T. R., Burlein J. E., Benson L. A., Bennett L. T., Bansal G. P., Young J. F., Lee M. H., Hatfull G. F. New use of BCG for recombinant vaccines. Nature. 1991 Jun 6;351(6326):456–460. doi: 10.1038/351456a0. [DOI] [PubMed] [Google Scholar]
  29. Telenti A., Imboden P., Marchesi F., Lowrie D., Cole S., Colston M. J., Matter L., Schopfer K., Bodmer T. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet. 1993 Mar 13;341(8846):647–650. doi: 10.1016/0140-6736(93)90417-f. [DOI] [PubMed] [Google Scholar]
  30. Telenti A., Imboden P., Marchesi F., Schmidheini T., Bodmer T. Direct, automated detection of rifampin-resistant Mycobacterium tuberculosis by polymerase chain reaction and single-strand conformation polymorphism analysis. Antimicrob Agents Chemother. 1993 Oct;37(10):2054–2058. doi: 10.1128/aac.37.10.2054. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Turett G. S., Telzak E. E., Torian L. V., Blum S., Alland D., Weisfuse I., Fazal B. A. Improved outcomes for patients with multidrug-resistant tuberculosis. Clin Infect Dis. 1995 Nov;21(5):1238–1244. doi: 10.1093/clinids/21.5.1238. [DOI] [PubMed] [Google Scholar]
  32. Wayne L. G. Simple pyrazinamidase and urease tests for routine identification of mycobacteria. Am Rev Respir Dis. 1974 Jan;109(1):147–151. doi: 10.1164/arrd.1974.109.1.147. [DOI] [PubMed] [Google Scholar]
  33. Williams D. L., Waguespack C., Eisenach K., Crawford J. T., Portaels F., Salfinger M., Nolan C. M., Abe C., Sticht-Groh V., Gillis T. P. Characterization of rifampin-resistance in pathogenic mycobacteria. Antimicrob Agents Chemother. 1994 Oct;38(10):2380–2386. doi: 10.1128/aac.38.10.2380. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Zhang Y., Garbe T., Young D. Transformation with katG restores isoniazid-sensitivity in Mycobacterium tuberculosis isolates resistant to a range of drug concentrations. Mol Microbiol. 1993 May;8(3):521–524. doi: 10.1111/j.1365-2958.1993.tb01596.x. [DOI] [PubMed] [Google Scholar]
  35. Zhang Y., Heym B., Allen B., Young D., Cole S. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature. 1992 Aug 13;358(6387):591–593. doi: 10.1038/358591a0. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES